2DR Stock Overview
A medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2DR from our risk checks.
Inspire Medical Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$162.75 |
| 52 Week High | US$233.30 |
| 52 Week Low | US$114.65 |
| Beta | 1.36 |
| 11 Month Change | -9.66% |
| 3 Month Change | -4.26% |
| 1 Year Change | 28.15% |
| 33 Year Change | -29.85% |
| 5 Year Change | 175.85% |
| Change since IPO | 470.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2DR | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -12.1% | -3.7% | -0.5% |
| 1Y | 28.1% | -4.2% | 8.3% |
Return vs Industry: 2DR exceeded the German Medical Equipment industry which returned -4.3% over the past year.
Return vs Market: 2DR exceeded the German Market which returned 8.3% over the past year.
Price Volatility
| 2DR volatility | |
|---|---|
| 2DR Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2DR has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 2DR's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 1,011 | Tim Herbert | www.inspiresleep.com |
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway.
Inspire Medical Systems, Inc. Fundamentals Summary
| 2DR fundamental statistics | |
|---|---|
| Market cap | €4.92b |
| Earnings (TTM) | €31.39m |
| Revenue (TTM) | €717.74m |
156.6x
P/E Ratio6.8x
P/S RatioIs 2DR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2DR income statement (TTM) | |
|---|---|
| Revenue | US$755.59m |
| Cost of Revenue | US$115.05m |
| Gross Profit | US$640.54m |
| Other Expenses | US$607.49m |
| Earnings | US$33.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.10 |
| Gross Margin | 84.77% |
| Net Profit Margin | 4.37% |
| Debt/Equity Ratio | 0% |
How did 2DR perform over the long term?
See historical performance and comparison